How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,169 results for

Life-Threatening Drug-Induced Rashes

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Prophylactic EVOZAC® Calming Skin Spray for EGFR-TKIs Associated Rash Eruption in NSCLC

Prophylactic EVOZAC® Calming Skin Spray for EGFR-TKIs Associated Rash Eruption in NSCLC Prophylactic EVOZAC® Calming Skin Spray for EGFR-TKIs Associated Rash Eruption in NSCLC - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Prophylactic EVOZAC® Calming Skin Spray for EGFR-TKIs Associated Rash Eruption in NSCLC The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01528488 Recruitment Status : Completed First Posted : February 8, 2012 Last Update Posted : November 5, 2013 Sponsor: Sun Yat-sen University

2012 Clinical Trials

102. Febuxostat-induced agranulocytosis in an end-stage renal disease patient: A case report. (Full text)

Febuxostat-induced agranulocytosis in an end-stage renal disease patient: A case report. Febuxostat, a nonpurine xanthine oxidase inhibitor, is approved as the first-line urate-lowering therapy in gout patients with normal renal function or mild to moderate renal impairment. The most common adverse effects of febuxostat are liver function test abnormalities, diarrhea, and skin rash. However, there is insufficient data in patients with severe renal impairment and end-stage renal disease (ESRD (...) showed myeloid hypoplasia without evidence of hematologic neoplasms.As febuxostat use may become more common in the population of advanced renal failure, clinicians should be aware of this rare but potentially life-threatening adverse effect. Based on our experience, close monitoring hemogram and immediate discontinuation of this medication may prevent serious consequences.

2017 Medicine PubMed

103. Delayed type hypersensitivity reactions induced by proton pump inhibitors: a clinical and in vitro T cell reactivity study. (PubMed)

Delayed type hypersensitivity reactions induced by proton pump inhibitors: a clinical and in vitro T cell reactivity study. Proton pump inhibitors (PPIs) have been known to induce type I hypersensitivity reactions. However, severe delayed-type hypersensitivity reactions (DHR) induced by PPI, such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), or drug rash with eosinophilia and systemic symptoms (DRESS), are rarely reported. We conducted a study of a large series of PPI (...) reactions, whereas three patients developed cross-hypersensitivity reactions to alternative structurally similar PPI. The cross-reactivity to structurally similar PPI was also observed in LAT assay.PPIs have the potential to induce life-threatening DHR. In patients when PPI is necessary for treatment, switching to structurally different alternatives should be considered.© 2017 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

2017 Allergy

104. Monocenter, Open Label Clinical Investigation on the Treatment of Radiation Induced Dermatitis With Xonrid®

Monocenter, Open Label Clinical Investigation on the Treatment of Radiation Induced Dermatitis With Xonrid® Monocenter, Open Label Clinical Investigation on the Treatment of Radiation Induced Dermatitis With Xonrid® - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. Monocenter, Open Label Clinical Investigation on the Treatment of Radiation Induced Dermatitis With Xonrid® The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier

2017 Clinical Trials

105. A Study of Topical Steroids as Preemptive Therapy for EGFR Inhibitor-Induced Papulopustular Eruption

(EGFRI) treatment in cancer patients. Participants will be followed up for 6 weeks of twice daily application of triamcinolone cream to the face, chest, and back. Condition or disease Intervention/treatment Phase Acneiform Rash Papulopustular Eruption Drug: Triamcinolone Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 84 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open (...) will be administered concomitantly as standard of care treatment. Drug: Triamcinolone 6 weeks of twice daily application of 0.1% triamcinolone cream to the face, chest, and back. Outcome Measures Go to Primary Outcome Measures : % of participants with grade 2 rash or higher [ Time Frame: 6 weeks ] To assess the difference in percentage of participants who develop a grade 2 or greater rash in the control group as compared to the case group of preemptive treatment with topical steroids (triamcinolone 0.1% cream

2017 Clinical Trials

106. Neutropenia induced by high-dose intravenous benzylpenicillin in treating neurosyphilis: Does it really matter? (Full text)

Neutropenia induced by high-dose intravenous benzylpenicillin in treating neurosyphilis: Does it really matter? Prompt therapy with high-dose intravenous benzylpenicillin for a prolonged period is critical for neurosyphilis patients to avoid irreversible sequelae. However, life-threatening neutropenia has been reported as a complication of prolonged therapy with high doses of benzylpenicillin when treating other diseases. This study aimed to investigate the incidence, presentation, management (...) and prognosis of benzylpenicillin-induced neutropenia in treating neurosyphilis based on a large sample of syphilis patients in Shanghai.Between 1st January 2013 and 31st December 2015, 1367 patients with neurosyphilis were treated with benzylpenicillin, 578 of whom were eligible for recruitment to this study. Among patients without medical co-morbidities, the total incidence of benzylpenicillin-induced neutropenia and severe neutropenia was 2.42% (95% CI: 1.38-4.13%) and 0.35% (95% CI: 0.06-1.39

2017 PLoS neglected tropical diseases PubMed

107. Oxcarbazepine-induced Stevens–Johnson syndrome: a pediatric case report (Full text)

Oxcarbazepine-induced Stevens–Johnson syndrome: a pediatric case report Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis are two rare but life-threatening diseases characterized by detachment of epidermis, bullous skin lesions and mucous membrane erosions. Anti-epileptic drugs are highly suspected to be the causative agents. Although carbamazepine (CBZ) is the most associated anti-epileptic drug, oxcarbazepine (OXC), which is a monohydrated derivative of CBZ, is proposed (...) to be safer because of the different metabolism of the two drugs. Herein, we report a case of SJS induced by oxcarbazepine. A 6-year-old boy with benign rolandic epilepsy, admitted to our hospital with generalized maculopapular rash after starting oxcarbazepine. The diagnosis of SJS was made with cytotoxic skin lesions and mucous membrane involvement. After discontinuing of the drug and topical corticosteroid initiation, the lesions were improved. We report this case to attract attention to the serious

2017 Oxford Medical Case Reports PubMed

108. Clinical Trial of a New Software ENgine for the Assessment & Optimization of Drug and Non-drug Therapy in Older peRsons

of Medicine, University College Cork ClinicalTrials.gov Identifier: Other Study ID Numbers: CRF-C-12-05 First Posted: March 27, 2014 Last Update Posted: January 21, 2019 Last Verified: January 2019 Keywords provided by Denis O'Mahony, University College Cork: Hospital acquired Elderly Additional relevant MeSH terms: Layout table for MeSH terms Drug-Related Side Effects and Adverse Reactions Chemically-Induced Disorders (...) Clinical Trial of a New Software ENgine for the Assessment & Optimization of Drug and Non-drug Therapy in Older peRsons Clinical Trial of a New Software ENgine for the Assessment & Optimization of Drug and Non-drug Therapy in Older peRsons - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2014 Clinical Trials

109. Does Acne Rash During Adolescence Predict Skin Reaction to Cetuximab

provided by (Responsible Party): Rambam Health Care Campus Study Details Study Description Go to Brief Summary: The hypothesis of this study is that patients who suffered from acne vulgaris during adolescence are at greater risk of developing acneiform skin rash due to cetuximab. Condition or disease Intervention/treatment Colorectal Cancer Metastatic Drug: Cetuximab Detailed Description: The hypothesis of this study is that patients who suffered from acne vulgaris during adolescence are at greater (...) Does Acne Rash During Adolescence Predict Skin Reaction to Cetuximab Does Acne Rash During Adolescence Predict Skin Reaction to Cetuximab - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Does Acne Rash

2011 Clinical Trials

110. Scrambler Therapy in Treating Chronic Pain in Patients With Rash From Varicella Zoster Virus Infection

problem Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) = 0, 1, or 2 Life expectancy >= 3 months (90 days) Ability to complete questionnaire(s) by themselves or with assistance Provide informed written consent Exclusion Criteria: Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown Pregnant women Patients with implantable drug delivery systems, e.g. Medtronic (...) Scrambler Therapy in Treating Chronic Pain in Patients With Rash From Varicella Zoster Virus Infection Scrambler Therapy in Treating Chronic Pain in Patients With Rash From Varicella Zoster Virus Infection - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please

2011 Clinical Trials

111. Patch testing is an effective method for the diagnosis of carbamazepine-induced drug reaction, eosinophilia and systemic symptoms (DRESS) syndrome in an 8-year-old girl. (PubMed)

Patch testing is an effective method for the diagnosis of carbamazepine-induced drug reaction, eosinophilia and systemic symptoms (DRESS) syndrome in an 8-year-old girl. Drug reaction, eosinophilia and systemic symptoms (DRESS) is an acute and life-threatening disease, characterised by fever, rash and systemic symptoms, including lymphadenopathy, abnormal liver function, interstitial nephritis, pulmonary and cardiac infiltrates and haematological abnormalities with eosinophilia and atypical (...) . Six weeks after complete recovery an epicutaneous patch test with carbamazepine was performed and a carbamazepine-induced positive skin reaction was observed at 48-h. Carbamazepine-induced DRESS syndrome is a rare entity in children. An epicutaneous patch test is a useful tool for identifying the inducing agent for the DRESS syndrome and for identifying a safe anticonvulsant drug.© 2012 The Authors. Australasian Journal of Dermatology © 2012 The Australasian College of Dermatologists.

2012 Australasian Journal of Dermatology

112. Days lost due to disability of diclofenac-induced adverse drug reactions (Full text)

Days lost due to disability of diclofenac-induced adverse drug reactions Disability Adjusted Life Years (DALY) is a widely used measure to quantify the burden of diseases or illness. DALYs for a disease is calculated as the sum of the Years of Life Lost (YLL) due to premature mortality in the population and the equivalent healthy Years Lost due to Disability (YLD). The only difference from the YLD and Days Lost due to Disability (DLD) calculation is that instead of considering the duration (...) of Adverse Drug Reaction (ADR) in years, it is calculated in days.DLD was measured for diclofenac tablets to prepare the ADR profile.The study was done on the patients (18-65 years old) attending the community pharmacy at Kasaragod district, South India, with prescription of diclofenac tablets. Patients reported ADRs on their next visit to the pharmacy or they had called to the provided phone number and reported it. Disability Weight (DW) was calculated in an analogue scale from 0-1. Zero represent

2012 Pharmacy Practice PubMed

113. Imatinib-induced Ototoxicity in a Patient with Gastrointestinal Stromal Tumor (GIST) (Full text)

Imatinib-induced Ototoxicity in a Patient with Gastrointestinal Stromal Tumor (GIST) Imatinib (Gleevec) is a biological agent that is approved for the treatment of chronic myeloid leukemia (CML) as well as gastrointestinal stromal tumor (GIST). The most frequently seen adverse effects in patients treated with imatinib include superficial edema, muscle cramps, musculoskeletal pain, rash, fatigue, headache, abdominal pain, and joint pain. Ototoxicity has rarely been reported except in two cases (...) . We report a case of bilateral irreversible sensorineural hearing loss (SNHL) caused by imatinib in a patient receiving this agent in the adjuvant setting. This case underlines the importance of early recognition of this potential toxicity that can impact the quality of life.

2016 Cureus PubMed

114. DRESS syndrome potentially induced by allopurinol and triggered by influenza vaccine (Full text)

DRESS syndrome potentially induced by allopurinol and triggered by influenza vaccine Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome, also known as drug-induced hypersensitivity syndrome (DHIS), is an acute, potentially life-threatening disease that includes skin rash, fever, haematological abnormalities and multiorgan involvement. Although its aetiopathogenesis is not exactly known, it is thought that inefficient drug detoxification leading to the accumulation of drug (...) reactive metabolites causes autoimmune responses in skin and some internal organs, alters immune responses and induces reactivation of viral infections in people who have genetic predisposition. To the best of our knowledge, only one case of DRESS syndrome has been reported after delivery of the influenza vaccine, but the drug that induced the reaction in that case was sulfasalazine. We report a case of a 64-year-old woman, receiving allopurinol, who developed DRESS syndrome after taking the influenza

2016 BMJ case reports PubMed

115. Dendritic cell vaccine and cytokine-induced killer cell therapy for the treatment of advanced non-small cell lung cancer (Full text)

did not receive DC-CIK, and acted as the control [non-immunotherapy group (group NI)]. Delayed-type hypersensitivity (DTH), quality of life (QOL) and safety were analyzed in group I. The follow-up period for the two groups was 489.2±160.4 days. The overall survival (OS) time was calculated using the Kaplan-Meier method. DTH was observed in 59 out of 97 evaluated patients (60.8%) and 67 out of 98 evaluated patients (68.4%) possessed an improved QOL. Fever and a skin rash occurred in 36 out of 98 (...) Dendritic cell vaccine and cytokine-induced killer cell therapy for the treatment of advanced non-small cell lung cancer The present study aimed to evaluate the survival time, immune response and safety of a dendritic cell (DC) vaccine and cytokine-induced killer (CIK) cell therapy (DC-CIK) in advanced non-small cell lung cancer (NSCLC). The present retrospective study enrolled 507 patients with advanced NSCLC; 99 patients received DC-CIK [immunotherapy group (group I)] and 408 matched patients

2016 Oncology letters PubMed

116. Efficacy, tolerability and impact on quality of life of clindamycin phosphate and benzoyl peroxide (duac® gel) for the treatment of cetuximab-associated acneiform eruption in patients with metastatic colorectal cancer. (PubMed)

Efficacy, tolerability and impact on quality of life of clindamycin phosphate and benzoyl peroxide (duac® gel) for the treatment of cetuximab-associated acneiform eruption in patients with metastatic colorectal cancer. Epidermal growth factor receptor inhibitors are recent antineoplastic treatments used for the treatment of some non-cutaneous tumours, which aberrantly express EGFR. Because of their specificity, these drugs have low systemic toxicity, but frequent undesired cutaneous effects (...) , the most common of which is an acneiform eruption, occurring after 1-3 weeks of treatment. Management of this rash is not well standardized.We evaluated efficacy, tolerability and impact on quality of life of a clindamycin phosphate 1.2%-benzoyl peroxide 5% gel in 12 male adults who developed acneiform eruption during treatment with cetuximab for metastatic colorectal cancer.Patients applied the clindamycin phosphate-benzoyl peroxide gel once daily, at evening, for 8 weeks. The Skin-Score was used

2015 Journal of Dermatological Treatment

117. Drug-eluting Stents vs. Drug-coated Balloon for Preventing Recurrent In-stent Restenosis

-medicated with steroids and diphenhydramine [e.g. rash] may be enrolled. Patients with true anaphylaxis to prior contrast media, however, should not be enrolled) Systemic (intravenous) Everolimus use within 12 months. Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study Non-cardiac co-morbid conditions are present with life expectancy <1 year or that may result in protocol non-compliance (per site (...) Drug-eluting Stents vs. Drug-coated Balloon for Preventing Recurrent In-stent Restenosis Drug-eluting Stents vs. Drug-coated Balloon for Preventing Recurrent In-stent Restenosis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies

2013 Clinical Trials

118. Safety and Feasibility of SurModics SurVeil (TM) Drug Coated Balloon

Safety and Feasibility of SurModics SurVeil (TM) Drug Coated Balloon Safety and Feasibility of SurModics SurVeil (TM) Drug Coated Balloon - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Safety (...) and Feasibility of SurModics SurVeil (TM) Drug Coated Balloon (PREVEIL) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02648620 Recruitment Status : Active, not recruiting First Posted : January 7, 2016 Last Update Posted : October 2, 2018 Sponsor: SurModics, Inc. Information provided by (Responsible Party

2015 Clinical Trials

119. Adverse drug reactions and organ damage: The skin. (PubMed)

Adverse drug reactions and organ damage: The skin. Cutaneous adverse drug reactions are frequent, affecting 2-3% of hospitalized patients and in one twentieth of them are potentially life-threatening. Almost any pharmacologic agent can induce skin reactions, and certain drug classes, such as non-steroidal anti-inflammatory drugs, antibiotics and antiepileptics, have drug eruption rates ranging from 1% to 5%. Cutaneous drug reactions recognize several different pathomechanisms: some skin (...) manifestations are immune-mediated like allergic reactions while others are the result of non immunological causes such as cumulative toxicity, photosensitivity, interaction with other drugs or different metabolic pathways. Cutaneous adverse drug reactions can be classified into two groups: common non-severe and rare life-threatening adverse drug reactions. Non-severe reactions are often exanthematous or urticarial whereas life-threatening reactions typically present with skin detachment or necrosis of large

2015 European journal of internal medicine

120. Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: the RELAX study. (Full text)

. The CD4 lymphocyte count remained stable (P = 0.096). Three (2.3%) patients had a detectable plasma HIV-1 RNA at the end of the study. Nine patients (6.9%) withdrew because of nevirapine-related toxicity (rash in seven patients and hypertransaminasaemia in two patients, none of which were > grade 2).The switch to nevirapine from a drug causing neuropsychiatric disturbances (primarily efavirenz) in subjects with virological suppression was effective in resolving those disturbances, with an improvement (...) Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: the RELAX study. The primary objective was to evaluate the improvement in neuropsychiatric symptoms attributed to an antiretroviral drug after that drug was substituted with nevirapine. The secondary objective was to evaluate the impact on patient adherence and quality of life.A prospective, observational study was carried out that included patients with HIV-1 plasma suppression

2015 HIV medicine PubMed

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>